The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.2136_2137del (p.Phe713fs)

CA658795274

556718 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: bc82aa6e-b8bc-4636-9a06-4ccb460b8747
Approved on: 2021-08-19
Published on: 2021-09-07

HGVS expressions

NM_000152.5:c.2136_2137del
NM_000152.5(GAA):c.2136_2137del (p.Phe713fs)
ENST00000302262.8:c.2136_2137del
ENST00000302262.7:c.2136_2137del
ENST00000390015.7:c.2136_2137del
ENST00000572080.1:n.555_556del
NM_000152.3:c.2136_2137del
NM_001079803.1:c.2136_2137del
NM_001079804.1:c.2136_2137del
NM_000152.4:c.2136_2137del
NM_001079803.2:c.2136_2137del
NM_001079804.2:c.2136_2137del
NM_001079803.3:c.2136_2137del
NM_001079804.3:c.2136_2137del
NC_000017.11:g.80113313_80113314del
CM000679.2:g.80113313_80113314del
NC_000017.10:g.78087112_78087113del
CM000679.1:g.78087112_78087113del
NC_000017.9:g.75701707_75701708del
NG_009822.1:g.16758_16759del
More

Pathogenic

Met criteria codes 4
PM3_Supporting PM2_Supporting PP4 PVS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.2136_2137del (p.Phe713ProfsTer23) variant in GAA is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 15/20, predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). A patient with this variant was reported to have deficient GAA activity and to be on enzyme replacement therapy for Pompe disease (PMID: 25614309, 27896092)(PP4). This patient is compound heterozygous, phase unknown, for the variant and a pathogenic variant in GAA, c.-32-13T>G ( PMID: 25614309, 27896092)(PM3_Supporting). There is a ClinVar entry for this variant (Variation ID: 556718; 1 star review status) with one submitter classifying the variant as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Storage Disorders VCEP (Specification Version 2.0): PVS1, PM2_Supporting, PM3_Supporting, PP4. (Classification approved on August 17th, 2021)
Met criteria codes
PM3_Supporting
One patient is compound heterozygous for the variant and c.-32-13T>G (pathogenic variant, phase unknown, 0.5 points)( PMID: 25614309, 27896092)(PM3_Supporting).
PM2_Supporting
This variant is absent in gnomAD v2.1.1 (PM2_Suporting).
PP4
One patient with this variant was reported to have deficient GAA activity (value not available) and to be on enzyme replacement therapy for Pompe disease (1 point) (PMID: 25614309, 27896092)(Total 1 point, PP4).
PVS1
NM_000152.5:c.2136_2137del (p.Phe713ProfsTer23) variant in GAA is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 15/20, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.